Company news
Palvella Therapeutics, Inc. news in 2024
Palvella Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 6, 2024
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 16, 2024
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 23, 2024
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
April 18, 2024
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
March 26, 2024
Decks in 2024
- Pieris Pharmaceuticals — Merger or Acquisition (July 2024)
Merger or acquisition · 35 slides · Jul 24, 2024
- Pieris Pharmaceuticals — Merger or Acquisition (July 2024)
Merger or acquisition · 16 slides · Jul 24, 2024